Clinical Trial Update: Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America [Phase 3]

View source ↗

Summary

Phase 3 study of flibanserin for hypoactive sexual desire disorder in postmenopausal women was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• Flibanserin (Flibanserin)

Snippet

Sponsor: Sprout Pharmaceuticals, Inc | Conditions: Sexual Dysfunctions, Psychological | Phase 3 | Status: TERMINATED | Results posted: 2014-06-17